HeartBeam (BEATW) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Loss: $5.3 million, or $0.15 per share, consistent with the previous quarter and analyst expectations.

Operating Cash Flow: Net cash used in operating activities was $3.2 million, an 8% decrease from the prior quarter, building on a 23% decrease in the previous quarter.

Cash Position: As of September 30, 2025, cash and cash equivalents stood at $1.9 million.

Focus on Cash Management: The company emphasized maintaining financial discipline while preparing for commercialization.

2Strategic Updates and Business Highlights

Product Overview: HeartBeam is developing a portable, cable-free ECG system capable of synthesizing a 12-Lead ECG, aimed at enhancing at-home heart health monitoring.

FDA Clearances: Achieved foundational FDA 510(k) clearance in December 2024. Anticipating clearance for the 12-Lead ECG synthesis software by year-end 2025.

Partnerships: Signed an agreement with HeartNexus for on-demand cardiologist services to interpret ECG readings, a critical component for the upcoming commercial launch.

Ecosystem Development: Building a comprehensive ecosystem around the HeartBeam system, including automated assessments, integration with wearables, and patient engagement features.

Intellectual Property: Secured three new patents, bringing the total to 24, and recognized as a leader in portable cardiac diagnostics.

3Forward Guidance and Outlook

Commercial Launch: Expected to begin early next year following FDA clearance. Initial focus on prominent concierge and preventive cardiology practices in Southern California and South Florida.

Sales Strategy: Plans to adopt a subscription model for users, with an emphasis on user experience and retention.

Market Penetration: Anticipated gradual rollout in 2026, with significant growth expected in the second half of the year as the business model is validated.

4Bad News, Challenges, or Points of Concern

Cash Constraints: The company is operating with a tight cash position, requiring careful monitoring and strategic funding to support growth and commercialization efforts.

Regulatory Risks: Dependence on timely FDA clearance for the 12-Lead ECG synthesis software, which is crucial for the commercial launch.

Market Entry Risks: Initial slow sales growth is expected as the company focuses on establishing workflows and user experience, with potential delays in scaling operations.

5Notable Q&A Insights

FDA Discussions: Management described ongoing interactions with the FDA as productive but did not provide specific details on the nature of inquiries.

Market Launch Strategy: Plans to start with a small number of high-profile accounts to gather feedback before expanding into additional territories.

Pricing Strategy: The company is considering a subscription model, with different pricing for symptomatic versus asymptomatic readings, although specific details are still being finalized.

Manufacturing Confidence: The company expressed confidence in its manufacturing capabilities, utilizing off-the-shelf components to ensure scalability.

Future Indications: Plans to pursue additional indications for myocardial infarction detection, with initial discussions already underway with the FDA. Overall, HeartBeam is positioned at a critical juncture with its innovative ECG technology, aiming for a successful commercial launch while navigating financial and regulatory challenges.